A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China

Parkinson Disease Clinical Trial

Official title: A Randomized, Double-blind, Placebo-controlled, Single-dose, Dose-escalation Tolerance and Pharmacokinetics Study of Oral Taking Finamine Tablets in Chinese Healthy-adult Subjects

Status Completed

Clinical Trial Summary

Design：Randomization, double-blind, single-center, single-dose, dose-escalation , placebo and parallel control Objectives：

1. To investigate the tolerability and safety of Chinese healthy adult subjects after a single oral administration of Finamine tablets;

2. To investigate the pharmacokinetic (PK) characteristics of Finamine tablets;

3. To provide dose setting basis for follow-up clinical studies. Investigational subject:Healthy-adult subjects in China

34 cases (including 4 cases of the pre- trial), of which the 150mg dose group is in the 4 cases of pre- trial (open, all accepted Finamine tablets orally, among whom, two receive it under fasting condition , and the other two receive it half an hour post a high-fat meal started). There are 6 cases in the formal trial (the subjects' ratio of investigational drug to placebo is 2:1). In all other dose groups, the subjects' ratio of investigational drug to placebo is 3:1.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Parkinson Disease

• NCT number: NCT04162275
• Study type: Interventional
• Source: Yiling Pharmaceutical Inc.
• Status: Completed
• Phase: Phase 1
• Start date: August 15, 2017
• Completion date: April 27, 2018